FDA Authorizes Marketing of Device That Can Improve Gait in Multiple Sclerosis Patients

FDA is taking an initiative to authorize the marketing of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients which can help patients with their motor deficit to some extent.

Are you aware of the condition called Multiple Sclerosis? This is one of the leading causes of neurological disability in many patients worldwide. It basically affects the nerve lining sheath. When this nerve sheath gets worn out, it results in electric shock, and pain may affecting their functions like talking, walking, and writing. Just imagine, the outer covering of the nerve sheath gets worms out causing intense damage to the actual nerve. It can get really painful and affect your walking and speech as the communication between the brain and body is carried by nerves. In the end, the nervous system gets disrupted resulting in slow walking and delayed speech. As age advances, the person suffering from Multiple Sclerosis gets further deteriorated. 

FDA comes to help the patients with Multiple Sclerosis

On 26th March 2021, the Food and Drug Administration (FDA) authorized the marketing of a device that can help patients of Multiple Sclerosis with gait deficit with mild to moderate symptoms. The device is to be used by a prescription only as an adjunct to supervise exercise training programs in patients with Multiple Sclerosis at age 22 or older. The device is called Portable Neuromodulation Stimulator (PoNS) is a neuromuscular stimulator which helps generate electrical impulses or trigeminal and facial nerve via the tongue to provide treatment for motor deficit problems. 

What is Multiple Sclerosis?

Multiple sclerosis is a chronic disease of the central nervous system. It is an autoimmune disorder, a condition in which the body mistakenly attacks its own healthy cells. Multiple Sclerosis is an unpredictable disease that affects people differently. The symptoms may vary from patient to patient and each may depend upon the area of damage. Multiple Sclerosis is the second cause of neurological disease and disability, after trauma. It affects more men than women. 

The real science behind Multiple Sclerosis 

As the name suggests, there is sclerosis or degradation of the outer sheath of the nerve which is also known as the myelin sheath. Myelin sheath is the outer fatty layer of the nerve. This myelin sheath protects the nerve fibers by providing a shield to the actual nerve. In Multiple Sclerosis , the myelin sheath is destroyed in many years affecting their functioning. This loss of myelin forms scar tissue called sclerosis. When the nerves are damaged in this way, they conduct electrical impulses to and from the brain. 

Causes for Multiple Sclerosis 

Autoimmune causes  Infectious agents such as virus  Environmental factors  Genetic factors 

Symptoms of Multiple Sclerosis 

The symptoms of Multiple Sclerosis are unpredictable. They may be mild or severe, short-term or long-lasting. Theory may appear in different combinations, dispensing on the area of the nervous system affected. The following are the most common symptoms of Multiple Sclerosis. But each person may have different symptoms. 

Blurred or double vision Red or green color distortion  Pain or loss of vision because of swelling of the optic nerve  Trouble walking  An abnormal feeling such as numbness or pricking sensation of pins and needles Muscle weakness in arms and legs  Difficulty in coordination while walking and standing  Spasticity: Involuntary increased tone of muscles Stiffness Of muscles Spasm of muscles  Fatigue on physical activity  Constant tiredness that does not go away  Loss of feeling  Speech problems: delayed of slurred speech  Tremors  Dizziness  Hearing loss  Bowel and Bladder problem  Depression  Changes in sexual function  Thinking inability or cognitive function  Difficulty in focus and attention  Memory loss  Poor judgment 

All you need to know about the Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients 

The FDA assesses the safety and effectiveness of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients through 2 clinical studies and retrospective analysis of the Real-World Clinical Data (RWD). The FDA is granted marked authorization of Portable Neuromodulation Stimulator (PoNS) for Multiple Sclerosis patients to Helius Medical Inc. 

Tags : #myhealth #medicircle #FDA #multiplesclerosis #PortableNeuromodulationStimulator

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Innovative AI Assistance Empowers Moscow Doctors to Detect Cervical Spine Issues through MRI ScansApril 20, 2024
Air India Express ties up with AISATS for AeroWash Automated Aircraft Exterior Cleanings April 19, 2024
IndoSup raises strategic funding led by CCI group promoters Naresh Sharma and Satish Sharma; investors include Yatra.com’s Rohan Mittal April 19, 2024
10 compelling reasons why choosing right media platform Is important in healthcareApril 19, 2024
Protecting Public Health: Proposed Guidelines for Pharmaceutical Product DistributionApril 19, 2024
What is Haemophilia: A Genetic Bleeding Disorder that has Affected 1,36,000 IndiansApril 19, 2024
Climate Change and Stroke Risk: Exploring the Impact of Temperature Fluctuations on Your Body April 19, 2024
The Extension and Benefits of ABHA Linking with CGHS Beneficiary ID: What You Need to KnowApril 19, 2024
Mental Health Issues Impact Studies in 3 out 4 Female Students: PeakMind StudyApril 18, 2024
Atal Incubation Centre – Centre for Cellular and Molecular Biology (AIC-CCMB) signs agreement for placement of equipment with Thermo Fisher Scientific to help advance innovation in India April 18, 2024
MiracleMe Introduces Revolutionary Orally Dissolving Plant-Based Nutrition ProductsApril 18, 2024
South Indian Bank signs MOU with Ashok Leyland Limited for Dealer FinancingApril 18, 2024
Serum Institute of India Partners with Oxford University to Develop Meningitis-B VaccineApril 18, 2024
Ethical Concerns Arise: Nestlé Accused of Adding Sugar and Honey to Infant Formula and Breakfast Cereals in Low-Income CountriesApril 18, 2024
Empowering India's Youth: IG Drones & AASSC Launch Drone Skill Program, to Upskill 10M YouthApril 17, 2024
Autonomix Medical Inc. Covered in Benzinga Article Highlighting Innovative Nerve Treatment TechnologyApril 17, 2024
Top 5 online learning platform for learnersApril 17, 2024
Broad-Spectrum RNA Vaccine Breakthrough for Enhanced Virus ProtectionApril 17, 2024
The Impact of Excessive Internet Usage on School Absence: Finnish Study Reveals Key FindingsApril 17, 2024
Uncovering Delhi's Illegal Fertility Centre Operations: Insights from Recent Child Trafficking CasesApril 17, 2024